- Home
- SUNS vs VIGL Comparison
SUNS vs VIGL Comparison
Compare SUNS & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUNS
- VIGL
- Stock Information
- Founded
- SUNS 2023
- VIGL 2020
- Country
- SUNS United States
- VIGL United States
- Employees
- SUNS N/A
- VIGL N/A
- Industry
- SUNS Real Estate Investment Trusts
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- SUNS Real Estate
- VIGL Health Care
- Exchange
- SUNS Nasdaq
- VIGL Nasdaq
- Market Cap
- SUNS 104.3M
- VIGL 95.2M
- IPO Year
- SUNS N/A
- VIGL 2022
- Fundamental
- Price
- SUNS $13.59
- VIGL $1.70
- Analyst Decision
- SUNS Buy
- VIGL Buy
- Analyst Count
- SUNS 1
- VIGL 6
- Target Price
- SUNS $17.50
- VIGL $16.60
- AVG Volume (30 Days)
- SUNS 67.3K
- VIGL 387.1K
- Earning Date
- SUNS 02-15-2025
- VIGL 11-07-2024
- Dividend Yield
- SUNS 4.64%
- VIGL N/A
- EPS Growth
- SUNS N/A
- VIGL N/A
- EPS
- SUNS 0.03
- VIGL N/A
- Revenue
- SUNS $734,226.00
- VIGL N/A
- Revenue This Year
- SUNS N/A
- VIGL N/A
- Revenue Next Year
- SUNS N/A
- VIGL N/A
- P/E Ratio
- SUNS $133.71
- VIGL N/A
- Revenue Growth
- SUNS N/A
- VIGL N/A
- 52 Week Low
- SUNS $8.11
- VIGL $1.60
- 52 Week High
- SUNS $15.74
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- SUNS N/A
- VIGL 23.30
- Support Level
- SUNS N/A
- VIGL $1.60
- Resistance Level
- SUNS N/A
- VIGL $2.46
- Average True Range (ATR)
- SUNS 0.00
- VIGL 0.16
- MACD
- SUNS 0.00
- VIGL -0.02
- Stochastic Oscillator
- SUNS 0.00
- VIGL 11.63
About SUNS Sunrise Realty Trust Inc. Common Stock
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.